NASDAQ · LEXX

Lexaria Biosciences

Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and many more patents pending worldwide. Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery.

lexariabioscience.com Corporate Presentation

Create a free account to join, then verify your holdings.

Increases bio-absorption many-fold

Reduces time of onsest from 1-2 hours to minutes

Delivers drugs more effectively across the blood brain barrier

Improves tolerability

Increases bio-absorption many-fold

Reduces time of onsest from 1-2 hours to minutes

Delivers drugs more effectively across the blood brain barrier

Improves tolerability

Increases bio-absorption many-fold

Reduces time of onsest from 1-2 hours to minutes

Delivers drugs more effectively across the blood brain barrier

Improves tolerability

Increases bio-absorption many-fold

Reduces time of onsest from 1-2 hours to minutes

Delivers drugs more effectively across the blood brain barrier

Improves tolerability

Chat Updates Press Releases8 Q&A Polls Rewards Team3 About

Lexaria Biosciences Shareholder Chat

Morgan Chen2:49 PM

The DehydraTECH data is what keeps me here. Big optionality.

Casey Brooks11:49 AM

Been a holder since the IPO. OG club 💎

Sam Rivera2:49 PM

What are people hoping to hear on the next call?

Sasha Wells8:49 AM

Added more this week. Patient money.

Alex Park2:19 PM

Love having a verified-only space to actually discuss the science.

Not investment advice. Participants are verified shareholders and may hold positions in the companies discussed. Don't act on information posted here.